Acrivon Therapeutics (ACRV) Non-Current Assets (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Non-Current Assets of $8.6 million for Q1 2026, down 65.58% year-over-year from $25.0 million in Q1 2025, and down 7.12% quarter-over-quarter from $9.3 million in Q4 2025.
Acrivon Therapeutics (ACRV) Non-Current Assets (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Non-Current Assets for 6 consecutive years, with $8.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 65.58% year-over-year to $8.6 million; the TTM figure through Mar 2026 stood at $53.0 million (down 53.48% YoY), while the FY2025 annual figure was $9.3 million, down 38.02% from the prior year.
- Non-Current Assets retreated to $8.6 million in Q1 2026 per ACRV's latest filing, from $9.3 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $49.1 million in Q4 2022 and bottomed at $6.6 million in Q3 2023.
- Historically, Non-Current Assets has averaged $20.1 million across 5 years, with a median of $14.9 million in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Assets jumped 695.13% — and 2023, when it slumped 82.55%.
- Acrivon Therapeutics' Non-Current Assets stood at $49.1 million in 2022, then plunged by 82.55% to $8.6 million in 2023, then surged by 74.49% to $15.0 million in 2024, then plunged by 38.02% to $9.3 million in 2025, then slipped by 7.12% to $8.6 million in 2026.
- Business Quant data shows ACRV's Non-Current Assets at $8.6 million in Q1 2026, $9.3 million in Q4 2025, and $14.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.55 Bn | 78.55 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 59.81 Bn | 54.67 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.87 Bn | 28.56 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | Acrivon Therapeutics | 93.73 Mn | 93.73 Mn | - | 7.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.60 Mn |
| Mar 31, 2026 | 8.61 Mn |
| Dec 31, 2025 | 9.27 Mn |
| Sep 30, 2025 | 14.94 Mn |
| Jun 30, 2025 | 20.17 Mn |
| Mar 31, 2025 | 25.02 Mn |
| Dec 31, 2024 | 14.96 Mn |
| Sep 30, 2024 | 25.70 Mn |
| Jun 30, 2024 | 48.23 Mn |
| Mar 31, 2024 | 8.38 Mn |
| Dec 31, 2023 | 8.57 Mn |
| Sep 30, 2023 | 6.60 Mn |
| Jun 30, 2023 | 6.77 Mn |
| Mar 31, 2023 | 46.23 Mn |
| Dec 31, 2022 | 49.13 Mn |
| Sep 30, 2022 | 9.04 Mn |
| Dec 31, 2021 | 6.18 Mn |